v3.26.3
Segment Reporting - Schedule of Segment Information for the Reportable Segments (Details) - AUD ($)
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2024
Schedule of Segment Information for the Reportable Segments [Line Items]      
Hyper-immune products revenue $ 7,713,601 $ 7,287,002 $ 4,902,865
Cost of sales of goods (2,738,529) (2,521,903) (1,566,068)
Gross profit 4,975,072 4,765,099 3,336,797
Other income 1,169,869 1,411,505 3,408,199
Fair value losses to financial assets (557,676)
Net foreign exchange gains/(losses) (285,115) 12,183 (27,603)
Movement in inventory provision    
General and administrative expenses (4,305,555) (4,483,623) (4,555,726)
Research and development expenses (1,933,440) (3,597,296) (5,375,461)
Selling and marketing expenses (3,471,556) (3,452,416) (2,029,648)
Operating profit/(loss) (3,850,725) (5,344,548) (5,801,118)
Finance income 185,438 135,866 327,756
Finance costs (14,712) (7,305) (7,576)
Share of loss from associates (1,456,019)
Profit/(loss) for the year (3,679,999) (5,215,987) (6,936,957)
Assets      
Segment assets 13,151,698 10,129,842 15,549,969
Total assets 13,151,698 10,129,842 15,549,969
Liabilities      
Segment liabilities 1,986,671 2,060,787 2,840,525
Total liabilities 1,986,671 2,060,787 2,840,525
Research and Development [Member]      
Schedule of Segment Information for the Reportable Segments [Line Items]      
Hyper-immune products revenue
Cost of sales of goods
Gross profit
Other income 1,122,132 1,380,993 3,364,439
Fair value losses to financial assets    
Net foreign exchange gains/(losses)
Movement in inventory provision    
General and administrative expenses (562,960) (460,251)
Research and development expenses (1,933,440) (3,597,296) (5,375,461)
Selling and marketing expenses
Operating profit/(loss) (811,308) (2,779,263) (2,471,273)
Finance income
Finance costs
Share of loss from associates  
Profit/(loss) for the year (811,308) (2,779,263) (2,471,273)
Assets      
Segment assets 782,313 1,110,514 768,370
Total assets 782,313 1,110,514 768,370
Liabilities      
Segment liabilities 179,995 230,875 604,018
Total liabilities 179,995 230,875 604,018
Hyper-Immune Products [Member]      
Schedule of Segment Information for the Reportable Segments [Line Items]      
Hyper-immune products revenue 7,713,601 7,287,002 4,902,865
Cost of sales of goods (2,738,529) (2,521,903) (1,566,068)
Gross profit 4,975,072 4,765,099 3,336,797
Other income 47,737 30,512 43,760
Fair value losses to financial assets    
Net foreign exchange gains/(losses)
Movement in inventory provision    
General and administrative expenses (3,565)
Research and development expenses
Selling and marketing expenses (3,471,556) (3,452,416) (2,029,648)
Operating profit/(loss) 1,551,253 1,343,195 1,347,344
Finance income
Finance costs
Share of loss from associates  
Profit/(loss) for the year 1,551,253 1,343,195 1,347,344
Assets      
Segment assets 2,900,653 1,737,563 2,845,096
Total assets 2,900,653 1,737,563 2,845,096
Liabilities      
Segment liabilities 744,280 617,461 206,524
Total liabilities 744,280 617,461 206,524
Corporate [Member]      
Schedule of Segment Information for the Reportable Segments [Line Items]      
Hyper-immune products revenue
Cost of sales of goods
Gross profit
Other income
Fair value losses to financial assets     (557,676)
Net foreign exchange gains/(losses) (285,115) 12,183 (27,603)
Movement in inventory provision    
General and administrative expenses (4,305,555) (3,920,663) (4,091,910)
Research and development expenses
Selling and marketing expenses
Operating profit/(loss) (4,590,670) (3,908,480) (4,677,189)
Finance income 185,438 135,866 327,756
Finance costs (14,712) (7,305) (7,576)
Share of loss from associates   (1,456,019)
Profit/(loss) for the year (4,419,944) (3,779,919) (5,813,028)
Assets      
Segment assets 9,468,732 7,281,765 11,936,503
Total assets 9,468,732 7,281,765 11,936,503
Liabilities      
Segment liabilities 1,062,396 1,212,451 2,029,983
Total liabilities $ 1,062,396 $ 1,212,451 $ 2,029,983